Scholarlink

<p>Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. Sorafenib (SB) remains an option for advanced HCC in patients who cannot receive, or do not respond to, immunotherapy. Safranal (SF), a bioactive saffron compound, possesses anti-inflammatory and anticancer properties. This study evaluated SF with SB in a diethylnitrosamine-induced cirrhosis–HCC rat model. Rats were assigned to control, HCC, HCC + SB, HCC + SF, and HCC + SF + SB groups and treated for three weeks. Liver morphology, function, histology, apoptosis, cell proliferation, transcriptomics, and metabolomics analyses were assessed. Combination therapy inhibited hepatic nodules and restored liver architecture. Biochemical and histopathological analyses confirmed improved liver function, reduced fibrosis, vacuolation, and decreased α-SMA expression. Combined treatment improved apoptosis, antiproliferative effects and caused G2/M cell cycle arrest. Inflammatory markers (TNF-α, NF-κB, COX-2, MMP9, and β-catenin) were downregulated. Multiomics confirmed modulation of apoptosis, inflammation, oxidative stress, and metabolic pathways. SF potentiates a promising anti-HCC therapeutic efficacy of SB.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Safranal improves the anticancer efficacy of sorafenib via transcriptomic reprogramming and metabolomic changes in a rat model of diethylnitrosamine-induced cirrhosis–hepatocellular carcinoma

  • 期刊论文

  • 发表日期：

    2026年6月26日

查看全文
  • Ameera Al Mansoori,
  • Badriya Baig,
  • Rania Harati,
  • Reem Sami Alhamidi,
  • Alaaeldin A. Hamza,
  • Suhail Al-Salam,
  • Anne Le,
  • Cissy Zhang,
  • Pratik Khare,
  • Rifat Hamoudi,
  • Amr Amin

摘要

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. Sorafenib (SB) remains an option for advanced HCC in patients who cannot receive, or do not respond to, immunotherapy. Safranal (SF), a bioactive saffron compound, possesses anti-inflammatory and anticancer properties. This study evaluated SF with SB in a diethylnitrosamine-induced cirrhosis–HCC rat model. Rats were assigned to control, HCC, HCC + SB, HCC + SF, and HCC + SF + SB groups and treated for three weeks. Liver morphology, function, histology, apoptosis, cell proliferation, transcriptomics, and metabolomics analyses were assessed. Combination therapy inhibited hepatic nodules and restored liver architecture. Biochemical and histopathological analyses confirmed improved liver function, reduced fibrosis, vacuolation, and decreased α-SMA expression. Combined treatment improved apoptosis, antiproliferative effects and caused G2/M cell cycle arrest. Inflammatory markers (TNF-α, NF-κB, COX-2, MMP9, and β-catenin) were downregulated. Multiomics confirmed modulation of apoptosis, inflammation, oxidative stress, and metabolic pathways. SF potentiates a promising anti-HCC therapeutic efficacy of SB.